https://orcid.org/0000-0002-7398-4616
References
- Garnier N, Redstone GG, Dahabieh MS, et al. The novel arsenical darinaparsin is transported by cystine importing systems. Mol Pharmacol. 2014;85(4):576–585. doi:10.1124/mol.113.089433
- Hosein PJ, Craig MD, Tallman MS, et al. A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin’s and non-Hodgkin’s lymphoma. Am J Hematol. 2012;87(1):111–114. doi:10.1002/ajh.22232
- Kim WS, Fukuhara N, Yoon DH, et al. Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian Phase 2 study. Blood Adv. 2023;7(17):4903–4912. doi:10.1182/bloodadvances.2022008615
- Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-1545
- Tanzima Nuhat S, Sakata-Yanagimoto M, Komori D, et al. Droplet digital polymerase chain reaction assay and peptide nucleic acid-locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T-cell lymphoma. Cancer Sci. 2018;109(5):1682–1689. doi:10.1111/cas.13557
- Ghosh SK, Perrine SP, Williams RM, et al. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood. 2012;119(4):1008–1017. doi:10.1182/blood-2011-06-362434
- Willenbrock K, Brauninger A, Hansmann ML. Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein–Barr virus-infected cells in early cases. Br J Haematol. 2007;138(6):733–739. doi:10.1111/j.1365-2141.2007.06725.x
- Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137(16):2161–2170. doi:10.1182/blood.2020009004
- Bourbon E, Maucort-Boulch D, Fontaine J, et al. Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. Blood Adv. 2021;5(16):3227–3239. doi:10.1182/bloodadvances.2021004515
- Montes-Moreno S, Odqvist L, Diaz-Perez JA, et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol. 2012;25(7):968–982. doi:10.1038/modpathol.2012.52
- Kataoka K, Miyoshi H, Sakata S, et al. Frequent structural variations involving programmed death ligands in Epstein–Barr virus-associated lymphomas. Leukemia. 2019;33(7):1687–1699. doi:10.1038/s41375-019-0380-5
- Li Y, Xu-Monette ZY, Abramson J, et al. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential. Blood Adv. 2023;7(7):1308–1311. doi:10.1182/bloodadvances.2022008550
- Malpica L, Marques-Piubelli ML, Beltran BE, et al. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022;97(7):951–965. doi:10.1002/ajh.26579
- Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113(20):4885–4893. doi:10.1182/blood-2008-08-175208
- Liang JH, Lu TX, Tian T, et al. Epstein–Barr virus (EBV) DNA in whole blood as a superior prognostic and monitoring factor than EBV-encoded small RNA in situ hybridization in diffuse large B-cell lymphoma. Clin Microbiol Infect. 2015;21(6):596–602. doi:10.1016/j.cmi.2015.02.017